ABT-<wbr/>199

ABT-199

CAT N°: 16233
Price:

From 79.00 67.15

B-cell lymphoma/leukemia 2 (Bcl-2) is an anti-apoptotic protein that controls cell survival by binding the BH3 domains of pro-death BAD and BAK proteins and preventing permeabilization of the mitochondrial outer membrane. This protein is tightly regulated for the homeostasis between cell growth and cell death. The gene that encodes this protein is considered an oncogene; its disruption can promote the survival of cancer cells.{27581} ABT-199 is a BH3 mimetic that selectively inhibits Bcl-2 with subnanomolar affinity (Ki is = 48 and 245 nM, respectively).{27580} ABT-199 inhibits the growth of Bcl-2-dependent cell lines and in vivo tumor xenografts.{27580} This compound has shown antileukemic activity in patients with refractory chronic lymphocytic leukemia and holds promise to address additional Bcl-2-dependent cancers.{27580,27583,27583}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide
  • Correlated keywords
    • 1379647-79-6 Bcl-2-selective inhibitor Bcl 2 Bcl2 Bcl-2 selectives apoptosis antitumor BH3 mimetic chronic lymphocytic leukemia cancer GDC0199 ABT199
  • Product Overview:
    B-cell lymphoma/leukemia 2 (Bcl-2) is an anti-apoptotic protein that controls cell survival by binding the BH3 domains of pro-death BAD and BAK proteins and preventing permeabilization of the mitochondrial outer membrane. This protein is tightly regulated for the homeostasis between cell growth and cell death. The gene that encodes this protein is considered an oncogene; its disruption can promote the survival of cancer cells.{27581} ABT-199 is a BH3 mimetic that selectively inhibits Bcl-2 with subnanomolar affinity (Ki is = 48 and 245 nM, respectively).{27580} ABT-199 inhibits the growth of Bcl-2-dependent cell lines and in vivo tumor xenografts.{27580} This compound has shown antileukemic activity in patients with refractory chronic lymphocytic leukemia and holds promise to address additional Bcl-2-dependent cancers.{27580,27583,27583}

We also advise you